Skip to main content
Erschienen in: International Journal of Colorectal Disease 5/2022

27.04.2022 | Original Article

Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis

verfasst von: Tetsuro Tominaga, Takashi Nonaka, Shosaburo Oyama, Toshio Shiraishi, Hiroaki Takeshita, Makoto Hisanaga, Hidetoshi Fukuoka, Akiko Fukuda, Yorihisa Sumida, Shintaro Hashimoto, Kazuo To, Kenji Tanaka, Terumitsu Sawai, Takeshi Nagayasu

Erschienen in: International Journal of Colorectal Disease | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although adjuvant chemotherapy (AC) using fluoro-pyrimidine and oxaliplatin (FU + oxaliplatin) is recommended after curative resection for locally advanced colon cancer patients, several randomized controlled trials have shown no additional effect of oxaliplatin in patients aged ≥ 70 years. Here, we examined the effectiveness of FU + oxaliplatin on the long-term outcome of old patients with a high risk of recurrence.

Methods

This multicenter, retrospective study included 346 colon cancer patients diagnosed with pathological T4 and/or N2 disease from 2016 to 2020. They were divided into an old group (≥ 70 years, n = 197) and a young group (< 70 years, n = 167). Propensity score matching was used to minimize selection bias, and 126 patients per group were matched.

Results

Before matching, the rates of poor performance status (p < 0.001) and the presence of comorbidities (76.1% vs. 47.9%, p < 0.001) were higher in the old group. Although all baseline factors were similar between groups, after matching, the AC rate was lower in the old group (45.2% vs. 65.1%, p = 0.002). In the old group, relapse-free (82.2% vs. 55.6% and 69.6%, p < 0.05) and overall survival (83.1% vs. 80.0% and 44.4%, p < 0.05) rates were significantly higher in the AC patients with FU + oxaliplatin than in the AC patients with only FU and the non-AC patients.

Conclusion

The selected old colon cancer patients with a high risk of recurrence gained an additional benefit with respect to prognosis from FU + oxaliplatin as AC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145–164CrossRef Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145–164CrossRef
2.
Zurück zum Zitat Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C (2017) Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 28:1023–1031CrossRef Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C (2017) Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 28:1023–1031CrossRef
3.
Zurück zum Zitat Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34CrossRef Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34CrossRef
4.
Zurück zum Zitat Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS et al (2017) Colon cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Nat Comp Cancer Net: JNCCN 15:370–398CrossRef Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS et al (2017) Colon cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Nat Comp Cancer Net: JNCCN 15:370–398CrossRef
5.
Zurück zum Zitat Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRef Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRef
6.
Zurück zum Zitat Lee H, Sha D, Foster NR, Shi Q, Alberts SR, Smyrk TC et al (2020) Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann Oncol 31:487–494CrossRef Lee H, Sha D, Foster NR, Shi Q, Alberts SR, Smyrk TC et al (2020) Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann Oncol 31:487–494CrossRef
7.
Zurück zum Zitat André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I et al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620–1629CrossRef André T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I et al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620–1629CrossRef
8.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
9.
Zurück zum Zitat Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S et al (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241–252CrossRef Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S et al (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241–252CrossRef
10.
Zurück zum Zitat Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol: Offi J Am Soc Clin Oncol 29:3768–3774CrossRef Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol: Offi J Am Soc Clin Oncol 29:3768–3774CrossRef
11.
Zurück zum Zitat André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol: Offi J Am Soc Clin Oncol 27:3109–3116CrossRef André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol: Offi J Am Soc Clin Oncol 27:3109–3116CrossRef
12.
Zurück zum Zitat McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E et al (2013) Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol: Offi J Am Soc Clin Oncol 31:2600–2606CrossRef McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E et al (2013) Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol: Offi J Am Soc Clin Oncol 31:2600–2606CrossRef
13.
Zurück zum Zitat Itatani Y, Kawada K, Sakai Y (2018) Treatment of elderly patients with colorectal cancer. Biomed Res Int 2018:2176056CrossRef Itatani Y, Kawada K, Sakai Y (2018) Treatment of elderly patients with colorectal cancer. Biomed Res Int 2018:2176056CrossRef
14.
Zurück zum Zitat Tominaga T, Nonaka T, Sumida Y, Hidaka S, Sawai T, Nagayasu T (2016) Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer. World J Surg Oncol 14:197CrossRef Tominaga T, Nonaka T, Sumida Y, Hidaka S, Sawai T, Nagayasu T (2016) Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer. World J Surg Oncol 14:197CrossRef
15.
Zurück zum Zitat Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP et al (2012) Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol: Offi J Am Soc Clin Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP et al (2012) Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol: Offi J Am Soc Clin
16.
Zurück zum Zitat Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC et al (1998) Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42:336–340CrossRef Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC et al (1998) Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42:336–340CrossRef
17.
Zurück zum Zitat Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R et al (2016) Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer. Clinical colorectal cancer 15:179–185. Oncology 30:2624–2634 Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R et al (2016) Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer. Clinical colorectal cancer 15:179–185. Oncology 30:2624–2634
18.
Zurück zum Zitat Bergquist JR, Thiels CA, Spindler BA, Shubert CR, Hayman AV, Kelley SR et al (2016) Benefit of postresection adjuvant chemotherapy for stage III colon cancer in octogenarians: analysis of the national cancer database. Dis Colon Rectum 59:1142–1149CrossRef Bergquist JR, Thiels CA, Spindler BA, Shubert CR, Hayman AV, Kelley SR et al (2016) Benefit of postresection adjuvant chemotherapy for stage III colon cancer in octogenarians: analysis of the national cancer database. Dis Colon Rectum 59:1142–1149CrossRef
19.
Zurück zum Zitat Besiroglu M, Demir T (2020) Which is the worse prognostic factor in patients with stage III colorectal cancer: tumor 4 or node 2?. J BUON: Offi J Balkan Union Oncol 25:1847–1853 Besiroglu M, Demir T (2020) Which is the worse prognostic factor in patients with stage III colorectal cancer: tumor 4 or node 2?. J BUON: Offi J Balkan Union Oncol 25:1847–1853
20.
Zurück zum Zitat Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol: Offi J Am Soc Clin Oncol 28264–271 Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol: Offi J Am Soc Clin Oncol 28264–271
21.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99 Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99
22.
Zurück zum Zitat Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ et al (2016) Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the Adjuvant Colon Cancer End Points (ACCENT) database. J Clin Oncol: Offi J Am Soc Clin Oncol 34:843–853CrossRef Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ et al (2016) Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the Adjuvant Colon Cancer End Points (ACCENT) database. J Clin Oncol: Offi J Am Soc Clin Oncol 34:843–853CrossRef
23.
Zurück zum Zitat Haller DG, O’Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W et al (2015) Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 26:715–724CrossRef Haller DG, O’Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W et al (2015) Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 26:715–724CrossRef
24.
Zurück zum Zitat Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N et al (2021) Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: findings from the ACCENT database of 4934 patients. Clin Colorectal Cancer 20:130–136CrossRef Margalit O, Boursi B, Rakez M, Thierry A, Yothers G, Wolmark N et al (2021) Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: findings from the ACCENT database of 4934 patients. Clin Colorectal Cancer 20:130–136CrossRef
25.
Zurück zum Zitat Nöpel-Dünnebacke S, Jütte H, Denz R, Feder IS, Kraeft AL, Lugnier C et al (2022) Causes of mortality in elderly UICC stage III colon cancer (CC) patients--tumor-related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry. Cancer Med. https://doi.org/10.1002/cam4.4540 Nöpel-Dünnebacke S, Jütte H, Denz R, Feder IS, Kraeft AL, Lugnier C et al (2022) Causes of mortality in elderly UICC stage III colon cancer (CC) patients--tumor-related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry. Cancer Med. https://​doi.​org/​10.​1002/​cam4.​4540
26.
Zurück zum Zitat Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097CrossRef Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097CrossRef
Metadaten
Titel
Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis
verfasst von
Tetsuro Tominaga
Takashi Nonaka
Shosaburo Oyama
Toshio Shiraishi
Hiroaki Takeshita
Makoto Hisanaga
Hidetoshi Fukuoka
Akiko Fukuda
Yorihisa Sumida
Shintaro Hashimoto
Kazuo To
Kenji Tanaka
Terumitsu Sawai
Takeshi Nagayasu
Publikationsdatum
27.04.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 5/2022
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-022-04159-x

Weitere Artikel der Ausgabe 5/2022

International Journal of Colorectal Disease 5/2022 Zur Ausgabe

Ist die Spülung bei Bohrlochtrepanation verzichtbar?

19.06.2024 Subduralhämatom Nachrichten

Wird ein chronisches Subduralhämatom per Bohrlochtrepanation entfernt, scheint eine subdurale Ausspülung mehr Vor- als Nachteile zu haben. Das legen Ergebnisse einer finnischen Studie nahe.

Was eine zu kleine Klappe für die Langzeitprognose bedeutet

18.06.2024 Aortenklappenersatz Nachrichten

Stellt sich nach der Implantation eines biologischen Aortenklappenersatzes die Prothese als zu klein für den Patienten heraus, hat das offenbar nur geringe Auswirkungen auf Langzeitüberleben und Reoperationsrisiko; zumindest solange die effektive Öffnungsfläche über 0,65 cm2/m2 liegt.

Antibiotika nach Appendektomie: Ist kürzer besser?

18.06.2024 Appendizitis Nachrichten

Nach einer Appendektomie wegen komplizierter Appendizitis scheint eine maximal dreitägige Antibiotikabehandlung hinreichend vor Komplikationen wie intraabdominellen Abszessen und Wundinfektionen zu schützen.

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.